BindingDB logo
myBDB logout

80 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27907876 46 Rational design and synthesis of 1,5-disubstituted tetrazoles as potent inhibitors of the MDM2-p53 interaction.EBI Jagiellonian University
28027532 1 Discovery of novel polycyclic spiro-fused carbocyclicoxindole-based anticancer agents.EBI Sichuan University and Collaborative Innovation Center for Biotherapy
27050782 16 Lead Optimization of 2-Phenylindolylglyoxylyldipeptide Murine Double Minute (MDM)2/Translocator Protein (TSPO) Dual Inhibitors for the Treatment of Gliomas.EBI University of Pisa
27080185 46 Structure-activity relationship study of 4-substituted piperidines at Leu26 moiety of novel p53-hDM2 inhibitors.EBI Merck Research Laboratories
26764190 4 Peptide-based inhibitors of protein-protein interactions.EBI Wroclaw University of Technology
26115576 15 Identification of a new p53/MDM2 inhibitor motif inspired by studies of chlorofusin.EBI University of East Anglia
26181851 26 Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.EBI Novartis Institutes for BioMedical Research
25396320 8 Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.EBI University of Michigan Comprehensive Cancer Center and Departments of Internal Medicine
25384157 37 Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interaction.EBI Amgen Inc.
25882531 8 Discovery of DS-5272 as a promising candidate: A potent and orally active p53-MDM2 interaction inhibitor.EBI Daiichi Sankyo Co., Ltd.
25042256 33 Optimization beyond AMG 232: discovery and SAR of sulfonamides on a piperidinone scaffold as potent inhibitors of the MDM2-p53 protein-protein interaction.EBI Amgen Inc.
25496041 43 Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles.EBI University of Michigan Comprehensive Cancer Center and Departments of Internal Medicine
24934571 14 Diphenylpyrroles: Novel p53 activators.EBI Cairo University
24900882 30 Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.EBI Merck Research Laboratories
24813735 17 Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy.EBI Second Military Medical University
24852275 15 Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2-p53 interaction.EBI Chinese Academy of Medical Science and Peking Union Medical College
24751445 15 Hot spot-based design of small-molecule inhibitors for protein-protein interactions.EBI University of Utah
24704029 14 Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction.EBI Novartis Institutes for BioMedical Research
24601644 113 Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteres.EBI Amgen Inc.
24548297 50 Selective and potent morpholinone inhibitors of the MDM2-p53 protein-protein interaction.EBI Amgen Inc.
24656661 11 Core modification of substituted piperidines as novel inhibitors of HDM2-p53 protein-protein interaction.EBI Merck Research Laboratories
24456472 67 Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development.EBI Amgen Inc.
24113239 26 5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2.EBI University of Nottingham
23808545 12 Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.EBI Roche Research Center
23786219 20 A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice.EBI University of Michigan
23726030 3 Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.EBI Kyoto University
23660015 5 Functional consequences of retro-inverso isomerization of a miniature protein inhibitor of the p53-MDM2 interaction.EBI Southwest University
22789708 15 Benzimidazole-2-one: a novel anchoring principle for antagonizing p53-Mdm2.EBI University of Pittsburgh
23541651 8 Inhibitors of the p53/hdm2 protein-protein interaction-path to the clinic.EBI Sanofi
23597064 68 Rational design and binding mode duality of MDM2-p53 inhibitors.EBI Amgen Inc.
23477941 1 Synthesis and evaluation of an imidazole derivative-fluorescein conjugate.EBI The University of Texas Health Science Center at Houston
22940704 23 Structure-activity relationship and antitumor activity of thio-benzodiazepines as p53-MDM2 protein-protein interaction inhibitors.EBI TBA
22524527 13 Structure-based design of novel inhibitors of the MDM2-p53 interaction.EBI Amgen Inc.
22227462 2 Chemical modulators working at pharmacological interface of target proteins.EBI Korea University College of Pharmacy Sejong-ro
22995624 20 Discovery of novel dihydroimidazothiazole derivatives as p53-MDM2 protein-protein interaction inhibitors: synthesis, biological evaluation and structure-activity relationships.EBI Daiichi Sankyo Co., Ltd
22694121 5 An ultrahigh affinity d-peptide antagonist Of MDM2.EBI University of Maryland
22624960 1 AM-8553: a novel MDM2 inhibitor with a promising outlook for potential clinical development.EBI University of Michigan Comprehensive Cancer Center
22230199 12 Unbiased binding assays for discovering small-molecule probes and drugs.EBI Broad Institute of Harvard and MIT
18752944 2 Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics.EBI Yale University
18680271 8 NMR screening for lead compounds using tryptophan-mutated proteins.EBI Institute for Biochemistry
18075579 9 Reaching for high-hanging fruit in drug discovery at protein-protein interfaces.EBI University of California at San Francisco
21314128 91 Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.EBI Newcastle University
21277201 35 Synthesis of cell-permeable stapled peptide dual inhibitors of the p53-Mdm2/Mdmx interactions via photoinduced cycloaddition.EBI State University of New York
20638853 12 Functional profiling of p53-binding sites in Hdm2 and Hdmx using a genetic selection system.EBI Purdue University
19928922 19 Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.EBI University of Michigan
19856920 10 Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.EBI Amgen Inc.
18977148 5 Discovery of new pyridoacridine alkaloids from Lissoclinum cf. badium that inhibit the ubiquitin ligase activity of Hdm2 and stabilize p53.EBI National Cancer Institute-Frederick
15780621 6 Structure-based design, synthesis, and biological evaluation of novel 1,4-diazepines as HDM2 antagonists.EBI Johnson & Johnson Pharmaceutical Research and Development
23043430 12 Pyrimidine-fused heterocycle derivatives as a novel class of inhibitors for a-glucosidase.BDB Shiraz University
28222243 5 Studies of the Binding of Modest Modulators of the Human Enzyme, Sirtuin 6, by STD NMR.BDB University at Albany
24523409 5 Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif.BDB Karlsruhe Institute of Technology
11408545 55 Rabbit alpha2-adrenoceptors: both platelets and adipocytes have alpha2A-pharmacology.BDB Glaxo SmithKline Pharmaceuticals
9694962 65 Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain.BDB Memorial Sloan-Kettering Cancer Center
9694916 7 Nonpeptide endothelin receptor antagonists. XI. Pharmacological characterization of SB 234551, a high-affinity and selective nonpeptide ETA receptor antagonist.BDB SmithKline Beecham Pharmaceuticals
9687574 21 Rat alpha3/beta4 subtype of neuronal nicotinic acetylcholine receptor stably expressed in a transfected cell line: pharmacology of ligand binding and function.BDB Georgetown University
9686407 633 Standard binding and functional assays related to medications development division testing for potential cocaine and opiate narcotic treatment medications.BDB SRI International
9669506 12 Affinities of venlafaxine and various reuptake inhibitors for the serotonin and norepinephrine transporters.BDB McGill University
9655904 1 In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.BDB Parke-Davis Pharmaceutical Research
9653897 59 Characterization of alpha1-adrenoceptor subtypes in the pig.BDB Uppsala University
 15 Investigation of Mechanism of Nitrogen Transfer in Glucosamine 6-Phosphate Synthase with the Use of Transition State AnalogsBDB Technical University of Gdansk
 10 Leflunomide's Bioactive Metabolite Has the Minimal Structural Requirements for the Efficient Inhibition of Human Dihydroorotate DehydrogenaseBDB NOVARTIS Pharma, Inc.
 7 Ortho- and para-(Difuoromethyl)aryl-beta-D-glucosides: A new class of enzyme-activated irreversible inhibitors of beta-glucosidasesBDB Merrell Dow Research Institute
 6 Design and Synthesis of Potent Inhibitors of Glutamine SynthetaseBDB Chevron Chemical Company
 16 Structure-activity relationships of carbocyclic influenza neuraminidase inhibitorsBDB Gilead Sciences Inc.
14690411 40 Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.BDB University of Florida College of Medicine